#United States #New York #Class Action #Faruqi & Faruqi #Alto Neuroscience

Faruqi & Faruqi Calls on Investors in Alto Neuroscience

Faruqi & Faruqi, LLP, a prominent securities law firm, is bringing attention to the class action lawsuit against Alto Neuroscience, Inc. (NYSE: ANRO). This action stems from significant losses experienced by investors following the company’s announcements regarding its product ALTO-100. In an urgent reminder, they note that the deadline for potential lead plaintiffs is set for September 19, 2025.

Investors who purchased or owned Alto stock between February 2, 2024, when the company went public, and October 22, 2024, are urged to take action, provided their losses exceed $50,000. Senior Partner James (Josh) Wilson has emphasized the importance of contacting the firm to discuss legal options. Interested parties are encouraged to reach out directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

In October 2024, Alto released disheartening news regarding the efficacy of ALTO-100 in treating Major Depressive Disorder (MDD), stating that it failed to meet its primary endpoint in a Phase 2b clinical trial. This declaration led to a staggering 69.99% drop in Alto's stock price, plummeting from $14.53 to $4.36.

The lawsuit alleges that Alto and its executives failed to disclose critical information regarding ALTO-100’s effectiveness and overstated its potential, affecting both investors and the company’s financial outlook.

Faruqi & Faruqi’s relentless pursuit for justice has seen successful recoveries of hundreds of millions for investors since its inception in 1995. They are now on a mission to hold Alto accountable for the losses shareholders endured due to what they consider misleading statements about the company's prospects.

Investors have the option to participate as class members, or potentially serve as a lead plaintiff—a role that involves directing and overseeing the litigation on behalf of others who have suffered similar losses. It's important to note that opting out of becoming a lead plaintiff will not affect an investor's ability to recover in the case. Faruqi & Faruqi also actively seeks information related to Alto’s practices, welcoming insights from whistleblowers, former employees, and shareholders who may provide valuable perspectives on the situation.

The firm is committed to ensuring all communications regarding this class action will remain confidential, reinforcing their diligent representation of investor interests. For ongoing updates about the legal proceedings against Alto Neuroscience, interested parties can visit www.faruqilaw.com/ANRO or follow Faruqi & Faruqi on LinkedIn, X, or Facebook.

The importance of this class action cannot be overstated, as it signifies a collective effort by investors to seek justice against corporate practices that significantly affect their financial well-being. Investors are reminded that prior results do not guarantee future outcomes, but participation in such legal avenues is a step toward accountability and recovery.